Tag: Valiant Laboratories

Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

Pharma company Valiant Laboratories is launching its maiden public issue on September 27, 2023. The IPO will comprise only a fresh issue of 1.09 crore equity shares by the company and there will be no offer-for-sale portion in the issue. The net proceeds from the IPO will be used to set up a manufacturing facility for specialty chemicals in Bharuch, Gujarat and for general corporate purposes. The company recorded a profit of Rs 29 crore for the year ended March FY23, up by 5.5 percent from previous year, and the revenue from operations increased by 14.5 percent to Rs 333.9 crore during the same period. Valiant Laboratories' shares are expected to make their debut on the BSE and NSE on October 9, 2023.